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ARTICLE
Inactivating mutations and X-ray crystal
structure of the tumor suppressor OPCML
reveal cancer-associated functions
James R. Birtley1,6,7, Mohammad Alomary2,7, Elisa Zanini2, Jane Antony 2, Zachary Maben1,
Grant C. Weaver 1, Claudia Von Arx2, Manuela Mura2, Aline T. Marinho2, Haonan Lu 2,
Eloise V.N. Morecroft2,3, Evdoxia Karali2, Naomi E. Chayen 4, Edward W. Tate 3, Mollie Jurewicz1,
Lawrence J. Stern 1,8, Chiara Recchi 2,8 & Hani Gabra 2,5,8
OPCML, a tumor suppressor gene, is frequently silenced epigenetically in ovarian and other
cancers. Here we report, by analysis of databases of tumor sequences, the observation of
OPCML somatic missense mutations from various tumor types and the impact of these
mutations on OPCML function, by solving the X-ray crystal structure of this glycoprotein to
2.65 Å resolution. OPCML consists of an extended arrangement of three immunoglobulin-like
domains and homodimerizes via a network of contacts between membrane-distal domains.
We report the generation of a panel of OPCML variants with representative clinical mutations
and demonstrate clear phenotypic effects in vitro and in vivo including changes to anchorage-
independent growth, interaction with activated cognate receptor tyrosine kinases, cellular
migration, invasion in vitro and tumor growth in vivo. Our results suggest that clinically
occurring somatic missense mutations in OPCML have the potential to contribute to
tumorigenesis in a variety of cancers.
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Opioid-binding protein cell-adhesion molecule like(OPCML) is a glycosylphosphatidylinositol (GPI)-anchored protein that localizes to the outer leaﬂet of the
plasma membrane and acts as a tumor suppressor (TS)1,2.
OPCML is a member of the IgLON superfamily, together with 4
other proteins (LSAMP, NEGR1, HNT, and IgLON5), amongst
which some have been hypothesized to act as tumor suppressors
or oncogenes3,4. However, functions of IgLON members have not
been fully characterized and their 3D structures remain unsolved.
Previously, we showed that OPCML is inactivated predominantly
by somatic methylation and loss of heterozygosity in more than
80% of ovarian cancer patients2. When re-expressed in cancer
cells, OPCML inhibits proliferation in vitro and tumorigenicity
in vivo2 by binding and downregulating a speciﬁc subset of
receptor tyrosine kinases (RTKs)5. Although somatic promoter
methylation is the predominant mechanism of silencing in
diverse tumor types1, we previously also reported a somatic
missense mutation at P95R in an ovarian cancer patient2. Pre-
liminary data indicated that this variant was expressed in similar
amounts as wild-type (WT) but was a loss-of-function mutant.
Here, we search for additional OPCML somatic mutations in the
TCGA and COSMIC DNA sequencing databases from a panel of
nearly 30,000 patients affected by different cancers. We show that
a number of patients exhibit somatic mutations of OPCML. In
order to understand how these clinical mutations might interfere
with OPCML’s tumor suppressor activity we then determine the
crystal structure of OPCML and show that these mutations fall
into several classes based on mutation type and location on the
protein structure. Selecting mutations representative of each class,
we characterize their biophysical properties and demonstrate
their functionality in in vitro and in vivo models. We further
demonstrate that particular mutations affect the oligomeric state
of OPCML, its interaction with cognate RTKs and its effect on a
range of phenotypes including migration, invasion, adhesion to
extracellular matrix proteins and in vivo tumorigenicity. These
ﬁndings reveal how the mutations result in functional/clinical
consequences, and these data have implications for under-
standing the mechanism of action of this class of membrane-
associated tumor suppressors.
Results
OPCML sustains point mutations in cancer patients. We ana-
lyzed tumor DNA sequence data from the TCGA and COSMIC
databases in order to identify possible clinical OPCML mutations.
We found point mutations in the OPCML gene in 287 out of 28,132
patients and these were distributed across all cancer types (Sup-
plementary Fig. 1A). Generally, the frequency of these clinical
mutations is uncommon, ranging from 5.5% in melanoma and
3.3% in colon, gastric, and bladder cancer to around 0.1% in cancers
such as breast and brain (Supplementary Fig. 1A). Nine mutations
were found to be splice site variants or stop codon-related altera-
tions (Supplementary Table 1). The remaining 278 changes were
missense mutations (Supplementary Table 1) and were mostly
scattered evenly along the entire OPCML sequence, with the
greatest number located in domain 1 (Supplementary Fig. 1B).
X-ray crystal structure of OPCML. To localize the clinical
mutations on the three-dimensional structure of OPCML and to
gain insights into their role in the tumor suppressor mechanism(s)
we crystallized soluble recombinant OPCML (residues 36–316)
and determined its structure using a combined single-wavelength
X-ray anomalous dispersion/molecular replacement approach
(Table 1). Structure solution was complicated initially by a high
degree of translational pseudosymmetry, but identiﬁcation of the
correct space group and non-crystallographic symmetry elements
allowed for chain tracing, which was followed by rounds of
automated and manual model building and reﬁnement (see
Methods). In the ﬁnal model (PDB entry 5UV6), 273 out of 286
residues in the mature OPCML protein were visualized (Sup-
plementary Figs. 2 and 3), with two molecules in the crystal-
lographic asymmetric unit. There are six potential N-linked
glycosylation sites (asparagines 44, 70, 140, 285, 293, and 306)
and glycans were modelled at residues 70, 293, and 306.
OPCML consists of three Ig-like domains termed D1, D2, and
D3, connected by short extended linkers (Fig. 1a, b, Supplemen-
tary Fig. 2). The OPCML homodimer resembles an inverted V
shape (Fig. 1a), with dimerization mediated by a membrane-distal
D1-D1 interface stabilized by a combination of hydrophobic
contacts, hydrogen bonds and salt bridges (Fig. 1c, Supplemen-
tary Fig. 4). This interface comprises 874 Å2 of buried surface area
and has a solvation free energy gain (ΔiG) on formation
calculated by PISA to be −9.5 kcal M−1. These values are larger
than for other intermolecular interaction sites observed in the
crystal, the next largest being crystal contacts mediated by the C-
terminal end of one molecule inserting between the B and G
strands of D1 in another with 554 Å2 buried surface area and
solvation free energy gain of −6.9 kcal M−1 (Supplementary
table 2 and Supplementary Fig. 5). Based on the quaternary
structure seen in the asymmetric unit, the dimer would be
anchored into the plasma membrane by two D3-linked GPI
anchors (Fig. 1a). The D3 C-terminal ends are located
approximately 180 Å apart, and thus the top of the D1
dimerization interface could extend above the plane of the
plasma membrane by ~73 Å (Fig. 1a).
The OPCML dimer is stabilized by reciprocal salt bridges
between Arg 65 of one monomer and Asp 80 of the other (Fig. 1c,
Table 1 Data collection, phasing, and reﬁnement statistics
for OPCML (MR-SAD)
Native K2PtCl4
Data collection
Space group P41212 I4122
Cell dimensions
a, b, c (Å) 93.6, 93.6, 262.2 98.8, 98.8, 267.1
α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å) 18.5–2.65 (2.74–2.65)a 48.3–3.17
(3.25–3.17)
Rsym 17.1 (273.6) 18.7 (301.5)
Rpim 4.7 (73.8) 3.6 (56.6)
I/σ(I) 9.7 (1.2) 11.5 (1.1)
CC1/2 100 (68.5) 100 (82.3)
Completeness (%) 95.8 (88.8) 100.0 (100.0)
Redundancy 14.4 (14.5) 28.2 (29.1)
Reﬁnement
Resolution (Å) 18.5–2.65 (2.74–2.65)
No. reﬂections 33374 (3021)
Rwork/Rfree 28.7/30.4
No. atoms 4392
Protein 4216
Ligand/ion (carbohydrate) 134
Water 42
B factors
Protein 84.6
Ligand/ion 91.0
Water 74.2
R.m.s deviations
Bond lengths (Å) 0.006
Bond angles (°) 0.99
NCS RMSD (Å)
All domains 1.10
D1 (43–134) 0.24
D2 (135–222) 0.19
D3 (223–319) 0.64
aValues in parentheses are for highest-resolution shell
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Supplementary Fig. 4). Below this lies a network of mainly
hydrophobic contacts mediated by the stacking of Trp 82, Ile 74,
Leu 69, Thr 114 and Arg 127 (Fig. 1c). A further 10 residues are
involved in minor contacts at the D1-D1 interface (Supplemen-
tary Figs. 3 and 4). Overall, the D1-D1 dimerization interface is
highly conserved since ﬁve of the seven key residues at the
interface are absolutely conserved across the IgLON family (i.e.
Leu 69, Ile 74, Asp 80, Trp 82, and Thr 114), with conservative
substitutions at the other positions (Arg 65 is Lys in LSAMP and
NEGR1 and Arg 127 is Gln in LSAMP, IGLON5, and NEGR1)
(Supplementary Fig. 3).
We also probed the oligomeric state of OPCML in solution
using small angle X-ray scattering (SAXS). SAXS has been widely
used to give information on size, shape, and orientation of
biological macromolecules in solution6. The scattering curve
calculated from the OPCML dimer ﬁts well with experimental
scattering data, while an OPCML monomer does not (Fig. 1e).
Pair-distance distribution function analysis7 (Fig. 1f) showed that
WT OPCML has a maximum calculated dimension of 189 Å, in
close agreement with the dimer seen in the crystal structure (the
monomer has a maximum calculated dimension of 116 Å). These
data showed OPCML to be a dimer in solution with a rigid
structure.
Tumor-associated mutations cluster on the OPCML structure.
We mapped the locations of clinical mutations on the crystal
structure and analysed their distribution. Ninety eight sites were
mutated a total of 243 times (Supplementary Fig. 1B) and,
interestingly, some sites were mutated substantially more fre-
quently than average, e.g. P95 was mutated eight times (Supple-
mentary Table 1 and Fig. 1d). When amino acids mutated at
higher frequency were mapped on to the crystal structure of
OPCML, it appeared that a much higher frequency occurs on one
side of the dimer than the other and that the mutations cluster in
patches (Fig. 2).
We ﬁrst focussed on a panel of mutations in D1, where
residues at the dimerization interface, glycosylation sites, and
exposed residues localized in the aforementioned patches could
be investigated for their potential impact on the tumor suppressor
properties of OPCML.
Mutations at the D1 interface disrupt homodimerization.
Members of the IgLON family have been reported to homo-
dimerize and/or heterodimerize for functionality8,9, but it is not
known whether OPCML dimerization is required for its tumor
suppressor function. We found that four of the seven salt bridge/
stacking residues (Arg 65, Asp 80, Thr 114, Arg 127) and three of
the 10 D1-D1 interface residues (Arg 71, Thr 73, Ile 84) are
mutated in cancer patients (Supplementary Table 1), suggesting
that disruption of dimerization could result in loss of function. To
test the role of OPCML dimerization in tumor suppression, we
investigated the R65L mutation. Recombinant R65L was secreted
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Fig. 1 Crystal structure of the OPCML homodimer. a Ribbon representation overlaid on a transparent surface illustrating the dimeric architecture of
OPCML. One monomer is colored blue and the other wheat. N-linked glycosylation (on asparagines 70, 293, and 306) are shown as orange spheres.
Location of P95 indicated by asterisk. N- and C- termini are indicated. Red parallel lines show the relative orientation of OPCML to the plasma membrane
(on the extracellular side). Scale bars are shown to illustrate maximum dimensions. b Represented the same as in a but viewed from the top. The dashed
rectangle represents key residues at the dimerization interface and these are shown in detail in c. c The D1-D1 homodimerization interface. Arg 65 from one
monomer forms a salt bridge with Asp of the other monomer. Below Arg 65 is a stacking interaction involving Trp 82, Ile 74, Leu 69, and Thr 114. Same
color scheme as in a, b . The alpha carbon backbone is shown as thin lines. d Stick representation of the β-turn encompassing residue P95, shown in wheat.
Residues 92–94 and 97–99 form part of the D and E β–strands, respectively. Hydrogen bonds are indicated by dashed lines. e Small angle X-ray scattering
analysis of WT OPCML. Scattering curves were measured and compared to calculated data of the dimer as seen in the crystal structure and of a
monomeric model of OPCML. The ﬁt to the dimer (χ= 0.50) matches more closely than to the monomer (χ= 2.35). f Pair-distance distribution function
curve for WT OPCML. The curve intercepts the x-axis at R= 189 Å, indicating the maximum atomic distance in a single scattering particle. This model-
independent parameter is consistent with the maximum manually measured dimension of the dimer structure (~180 Å), and is signiﬁcantly larger than the
maximum dimension of the monomer structure (~124 Å)
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at levels similar to WT in insect cells. However, when we
examined R65L by size-exclusion chromatography with multiple
angle laser light scattering (SEC-MALLS, Supplementary Fig. 6A),
or compared it to WT by gel ﬁltration (Supplementary Fig. 6B),
we found it to be predominantly a monomer in solution at
concentrations up to 32 μM (Supplementary Fig. 6C), with a Kd
at least 250-fold weaker than for WT OPCML (Supplementary
Fig. 6D). We examined the thermal stability of R65L using a
thermal shift assay and found it to melt at 51.5 °C, substantially
lower than WT (57 °C, Supplementary Fig. 6E), perhaps due to
the loss of quaternary structure. Furthermore, when WT and the
R65L mutant were extracted from transduced cells and analysed
by SDS-PAGE without prior heat denaturation, WT ran as a
dimer while R65L ran exclusively as a monomer (Fig. 3a),
demonstrating that WT OPCML exists as a dimer also in cells
and that the R65L mutation does indeed disrupt dimerization.
Loss of glycosylation leads to OPCML aggregation. We inves-
tigated the N70H mutation, which abolishes N-linked glycosyla-
tion at this position. Well-ordered glycans were observed at each
Asn 70 in the crystal structure, allowing modelling of NAG-
NAG-MAN glycosylation sequences. Eleven amino acids make
speciﬁc contacts with Asn 70 and the associated sugar residues
(Supplementary Figs. 3 and 4), and we found ﬁve of these to be
mutated in cancer patients (Arg 71, Thr 73, Asp 85, Arg 87, and
Asp 109). Asn 70 and the ﬁrst NAG residue are completely buried
by D1 and lie close to, but do not make speciﬁc contacts with, the
reciprocal D1. However, some residues that contact Asn 70 and
the glycans are also identiﬁed as D1-D1 contact residues (i.e. Arg
71, Thr 73, Leu 75, and Ser 83). Recombinant N70H gave a
different SDS-PAGE banding pattern, indicative of altered gly-
cosylation (Supplementary Fig. 6F), and secreted poorly com-
pared to WT OPCML, with expression reduced by at least 80%.
Moreover, we observed recombinant N70H to be an unstable
protein. It gave a strong ﬂuorescence signal at the beginning of
the thermal shift assay (Supplementary Fig. 6E) and exhibited
substantial aggregation by gel ﬁltration (Supplementary Fig. 6B).
This made analysis by SEC-MALLS impossible. Thus, N70H
disrupts OPCML glycosylation and protein stability.
D1 surface mutations do not affect protein stability. We pre-
viously observed a mutation at Pro 95 in a patient with ovarian
cancer2 and our sequencing analysis revealed several additional
mutations at this position (Supplementary Table 1). Pro 95 is
located in a type I β–turn, between β-strands D and E of D1
(Fig. 1d), in a solvent-exposed position (starred on Fig. 1a, b)
distal from the dimerization interface. Mutations at Pro 95 could
lead to disruption of this β–turn and hinder protein folding.
However, recombinant expression levels of P95R were indis-
tinguishable to that of WT, and P95R migrated similarly on SDS-
PAGE (Supplementary Fig. 6F). We also examined the thermal
stability of P95R and found it to melt at 58 °C, similar to WT
(57 °C, Supplementary Fig. 6E). Further, P95R was found to be a
dimer in solution using SEC-MALLS and migrated similarly to
WT by gel ﬁltration (Supplementary Figs. 6A and B). Thus, P95R
does not disrupt dimerization or protein stability.
R65L, N70H and P95R disrupt tumor suppressor function. To
evaluate the effect of these mutations on the tumor suppressor
function of OPCML, we used three different ovarian cancer cell
lines: SKOV3 and PEA1, which have mesenchymal character-
istics, and PEO1, which has epithelial characteristics10. These
were stably transduced with WT or mutant OPCML (R65L,
N70H, P95R) or an empty control vector (CTRL) and char-
acterized. All the corresponding proteins were expressed in the
three ovarian cancer cell lines at similar levels as shown by
western blot (Fig. 3a), and immunoﬂuorescence microscopy
conﬁrmed that they were membrane-localized (Fig. 3b). When
tested for their ability to invade or migrate in transwell assays
(with or without Matrigel respectively) and for their anchorage-
independent growth, WT OPCML completely abolished cell
migration in SKOV3 and PEA1 (PEO1 cells did not migrate at
all), and invasion and growth in all three cell lines compared to
control cells (Fig. 3c–e and Supplementary Fig. 7). However, all
the mutants showed loss of function in the three phenotypic
assays (Fig. 3c–e and Supplementary Fig. 7).
As we had previously shown that a recombinant form of
OPCML protein added exogenously to cancer cells can
recapitulate the tumor suppressor effect observed when the
protein is expressed endogenously by the cells themselves5, we
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investigated the effect of adding mutant recombinant OPCML
proteins in a 3D invasion model. Whereas pre-treatment with
WT OPCML protein completely blocked the serum-stimulated
invasion of cancer cells into the matrix, the cells pre-treated with
mutant protein were unable to impair invasion, corroborating our
ﬁndings in transduced cells (Fig. 3f).
Furthermore, under serum-stimulated conditions, we observed
that the expression of WT OPCML in transduced cells strongly
reduced the levels of total HER2 and phospho-HER2, in line with
our previous results5, but it also decreased the levels of phospho-
AKT without affecting its total levels (Fig. 3g), while all the
mutants had lost this function. Similarly, expression of WT
M
IG
RA
TI
O
N
N
um
be
r o
f m
ig
ra
tin
g 
ce
lls
IN
VA
SI
O
N
AN
CH
. I
ND
EP
.
G
RO
W
TH
ba
c
d
e
f
SKOV3
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
***
***
****
***
PEA1
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
****
****
****
****
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
0
50
100
150
N
um
be
r o
f c
ol
on
ie
s 
fo
rm
ed
N
um
be
r o
f c
ol
on
ie
s 
fo
rm
ed
N
um
be
r o
f c
ol
on
ie
s 
fo
rm
ed
SKOV3
****
**
***
****
SKOV3 PEA1 PEO1
CT
RL
O
PC
M
L
R
65
L
N
70
H
P9
5R
g
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
GAPDH
pAKT
AKT
pHER2
HER2
pEGFR
EGFR
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
SKOV3 PEA1 PEO1
O
PC
M
L
G
AP
DH
N
o
se
ru
m
 
Se
ru
m
Se
ru
m
+
 r
O
PC
M
L
72 h0 h
Se
ru
m
+
 r
R
65
L
Se
ru
m
+
 r
N
70
H
Se
ru
m
+
 r
P9
5R
 
72 h0 h
SS –
rO
PC
ML
rR
65
L
rN
70
H
rP9
5R
0
100
200
300
In
va
si
on
 a
re
a
***
****
****
***
**
+ 10% FBS
OP
CM
L
R6
5L
SKOV3
(non red)
O
PC
M
L
Ac
tin
0
500
1000
1500
2000
0
200
400
600
800
1000
N
um
be
r o
f m
ig
ra
tin
g 
ce
lls
N
um
be
r o
f i
nv
ad
in
g 
ce
lls
N
um
be
r o
f i
nv
ad
in
g 
ce
lls
N
um
be
r o
f i
nv
ad
in
g 
ce
lls
SKOV3
****
****
****
****
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
0
500
1000
1500
PEA1
****
***
***
***
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
0
200
400
600
800
1000
PEO1
****
****
****
****
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
0
500
1000
1500
2000
PEA1
****
****
***
***
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
0
50
100
150
200
PEO1
****
****
**** ****
CT
RL
OP
CM
L
R6
5L
N7
0H
P9
5R
0
500
1000
1500
2000
55 kDa
37 kDa
40 kDa
175 kDa
175 kDa
185 kDa
185 kDa
60 kDa
60 kDa
37 kDa
55 kDa
70 kDa
100 kDa
130 kDa
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10966-8 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3134 | https://doi.org/10.1038/s41467-019-10966-8 | www.nature.com/naturecommunications 5
OPCML in the colorectal cancer cell line HCT116 (Supplemen-
tary Fig. 8A) decreased the phosphorylation of ERK1/2 but the
OPCML mutants could not (Supplementary Fig. 8B).
D1 mutants have distinctive interactions with RTKs. To better
understand the mechanism behind the loss of function of mutants
and highlight possible differences, we analysed their ability to
interact with AXL and FGFR1, two known RTK partners of
OPCML. As we previously showed11, the interaction between
AXL and OPCML is triggered by the binding of AXL to its ligand
GAS6 (Fig. 4a). We observed by Proximity Ligation Assay (PLA,
or DuoLink) that this is the case also for the interaction between
FGFR1 and OPCML, which is stimulated by the addition of the
ligand FGF1 (Fig. 4b). When we analysed the monomeric R65L,
we found that it could not bind to either AXL or FGFR1, even
upon stimulation with the ligands (Fig. 4a, b). Unexpectedly, the
aggregated mutant N70H interacted with both receptors even in
the absence of ligands, perhaps due to its compromised folding.
Interestingly, we discovered that the surface-exposed P95R
mutant could still bind to FGFR1 (Fig. 4b), but it had lost its
ability to interact with AXL even after ligand stimulation (Fig. 4a)
and this selective loss of binding was conﬁrmed by a mammalian
2-hybrid assay (Fig. 4c, d). Similar results were obtained also in
HCT116 cells, where the addition of Gas6 stimulated the binding
of AXL to WT OPCML but not to the R65L and P95R mutants
(Supplementary Fig. 8C).
In order to further deﬁne the functional consequences of these
differential interactions, we analysed the effect of the different
mutations in a motility assay in SKOV3 cells stimulated with
GAS6 or FGF1. Control cells responded to the stimulation and
closed the gap, while WT OPCML blocked both GAS6- and
FGF1-induced motility (Fig. 4e). As expected from the PLA assay,
the R65L mutant, unable to interact with either AXL or FGF1,
could not prevent this stimulated motility (Fig. 4e). On the
contrary, the N70H mutant, which interacts with both AXL and
FGFR1, could inhibit gap closure and showed a phenotype similar
to WT OPCML (Fig. 4e). As expected, the P95R mutant could
still interact with FGFR1 and prevent FGF1-stimulated motility,
but, having lost its interaction with AXL, was unable to block
GAS6-mediated migration (Fig. 4e).
We then investigated the effect of the mutations on the
inhibition of downstream signalling. Typically, SKOV3 cells
respond to GAS6 and FGFR1 stimulation by inducing sustained
phosphorylation of the downstream AKT and ERK pathways and
OPCML-mediated inactivation of these downstream pathways
becomes visible 3 h after stimulation (Fig. 4f, g). As expected, the
monomeric R65L mutant could not inhibit the sustained
activation of AKT and ERK, while the N70H mutant inhibited
the initial activation, delaying the phosphorylation of both AKT
and ERK (Fig. 4f, g). In accord with the previous results, the P95R
mutant could not impair GAS6-induced signalling, but it
completely hindered FGF1 signalling (Fig. 4f, g). Additionally,
when we tested other clinically relevant amino acid substitutions
at P95 (P95L and P95S) in SKOV3 cells (Fig. 5a, b) in the context
of AXL inhibition, we found that these mutants did not interact
with AXL (Fig. 5c) and had no inhibitory effect on GAS6-
stimulated signalling (Fig. 5d), migration (Fig. 5e) or invasion
(Fig. 5f), underlying the importance of Proline 95 in the
interaction of OPCML with AXL.
As we previously found that expression of OPCML confers
sensitivity to the AXL inhibitor R42811, we tested the R65L,
N70H and P95R mutants in this context too. They all showed
IC50 values and caspase 3/7 activation levels very similar to those
of control cells (Fig. 4h, i), conﬁrming that all three mutations
abolish the ability of OPCML to permanently suppress AXL.
When we looked at the involvement of the single D1/D2/D3
domains in the OPCML-AXL interaction upon expression in
SKOV3 cells (Supplementary Fig. 9A) we found that D1 had a
stronger interaction with AXL in full medium compared to D2
and D3 (Supplementary Fig. 9B) and it also responded to
stimulation with Gas6 (Supplementary Fig. 9C). These results
reinforce the importance of this distal OPCML domain for the
regulation of AXL.
Arg71, the most frequently mutated amino acid in D1. Arg71 is
the most commonly altered residue in D1 (Supplementary
Table 1) being mutated nine times: seven times to cysteine and
once to histidine in colorectal cancer and glioblastoma. Arg71 is
located on the underside of the D1-D1 interface, and makes
contacts with the sugar moiety attached to asparagine 70 (Fig. 2
and Supplementary Fig. 4). We expressed R71C in SKOV3 cells
(Fig. 6a, b) and analysed its function in phenotypic assays. We
observed that R71C had lost its ability to inhibit migration
(Fig. 6c), invasion (Fig. 6d) and anchorage-independent growth
(Fig. 6e). Furthermore, it was unable to block ERK1/2 activation
in HCT116 colorectal cancer cells (Supplementary Fig. 8B).
Mutations in domains 2 and 3. Most D2 mutations (39 of the
69) are located between E201 and R214 (Supplementary Fig. 10)
and 24 of these mutations involve 4 surface-exposed residues
found close together on the D2 surface (R170, E201, S203, and
R214) (Fig. 2), Conversely, in D3 the location and incidence of
mutations seem to be spread evenly across the length of this
domain (Supplementary Fig. 10), most of the high frequency
mutations are localized in a stretch on the top portion on D3
(Fig. 2). We selected three mutations from D2 (E201Q, S203R,
and R214Q) and three mutations from D3 (K230R, K239N,
M278I) for further study. These six mutations were stably
expressed in SKOV3 cells (Fig. 6a, b) and their functions ana-
lysed. Whilst the expression of WT OPCML impaired cell
migration (Fig. 6c) and invasion (Fig. 6d) in transwell assays
upon serum stimulation, all the D2 and D3 mutants lost these
functions (Fig. 6c, d), as seen for the D1 mutants. Similarly, the
Fig. 3 R65L, N70H, and P95R mutants show loss of their tumor suppressor function in vitro. SKOV3, PEA1 and PEO1 ovarian cell lines were transduced with
an empty vector (CTRL), wild-type (OPCML) or mutant (R65L, N70H, and P95R) OPCML and analyzed for protein expression by western blot (a) and
protein expression/localization by confocal microscopy (b) with an anti-OPCML antibody. GAPDH or actin were used as loading controls in a. Samples in
the right panel in a were run without heat denaturation. Scale bar= 20 μm. Cells were then tested for migration (c) and invasion (d) in transwell assays
and for anchorage-independent growth in agarose (e). All the graphs show the mean ± s.d. of three independent experiments. Student t-test compares
CTRL and mutants to wild-type OPCML: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. f SKOV3 cells grown as spheroids were serum-starved, treated
with the indicated recombinant proteins (rOPCML, rR65L, rN70H, rP95R), embedded into Matrigel and then stimulated with serum. Invasion of the
spheroids was quantiﬁed after 3 days. Scale bar= 250 μm. The graphs show the mean ± s.e.m. of three independent experiments. Student t-test compares
controls and mutant recombinant proteins to wild-type rOPCML: **p < 0.01, ***p < 0.001. g SKOV3 cells expressing the indicated wild-type and mutant
OPCML were lysed and analyzed by western blot for the expression of total and phosphorylated levels of EGFR, HER2 and AKT. GAPDH was used as
loading control
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E201Q and the M278I mutants showed loss of function in
HCT116 cells (Supplementary Fig. 8B). However, when we tested
anchorage-independent growth in SKOV3 cells, all OPCML
clinical mutations demonstrated loss of function except for S203R
(Fig. 6e) suggesting different roles for the different mutations.
OPCML inhibits proliferation via its domains 2 and 3. Since
OPCML re-expression strongly decreases growth rate of cancer
cells2, the whole panel of mutants in the three domains was tested
in proliferation assays. Whereas D1 mutants did not lose the
ability to inhibit proliferation, all mutants in D2 and D3 were
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unable to inhibit growth (Fig. 7a), suggesting loss of function
through functional domain speciﬁcity.
OPCML promotes binding to collagen I mainly via domain 1.
Since the composition of the extracellular matrix is known to
have a key role in ovarian cancer progression and dissemina-
tion12, we investigated whether OPCML could promote or inhibit
adhesion on a variety of extracellular matrix components. We
found that WT OPCML promotes cell adhesion on collagen I
(Fig. 7b) and collagen IV (Fig. 7c), and that it hinders adhesion
on ﬁbronectin (Fig. 7d), laminin (Fig. 7e) and ﬁbrinogen (Sup-
plementary Fig. 11). We then analysed the adhesion properties of
the mutants and found that point mutations in each of the
domains were sufﬁcient to restore binding to ﬁbronectin, laminin
and ﬁbrinogen (Figs. 7d, e and Supplementary Fig. 11). However,
only mutations in D1, and to a lesser extent in D2, showed a
strongly attenuated adhesion to collagen I (and partially to col-
lagen IV) (Fig. 7b, c).
OPCML mutants block tumor suppressor functions in vivo.
The results presented above demonstrate the strong impact that
single point mutations have in inactivating OPCML’s tumor
suppressor function(s) in vitro. To expand these observations, we
tested the ability of these mutants to block tumorigenicity in vivo.
We examined ﬁrst the R65L, N70H, and P95R D1 mutants, using
SKOV3 ovarian carcinoma cells injected intraperitoneally in
immunocompromised athymic mice. Cells expressing WT
OPCML did not form visible tumors nor ascites in any of the
injected mice, while cells expressing the vector control and the
three mutants were able to give rise to tumor dissemination and
ascites, though to different extents depending on the mutation
(Fig. 8a). In particular, the R65L and P95R mutants formed
tumors and ascites very similarly to control cells (Fig. 8a), while
the N70H mutant, which is aggregated and had a more mixed
phenotype in vitro, presented a more attenuated phenotype and it
gave rise to small tumors in some mice (Fig. 8a). We also tested
representative mutations in D1 (R65L), D2 (R214Q), and D3
(M278I) in the chick chorio–allantoic membrane (CAM) assay
(Fig. 8b). The R65L mutant was chosen also as a measure to
compare the results in mice and CAM models. As evident in
Fig. 8b, the expression of WT OPCML prevented tumor growth
on the CAM, while all three clinical mutations were impaired in
this function and the cancer cells expressing them grew at least as
well as the control cells.
Discussion
OPCML is a frequently inactivated tumor suppressor in multiple
types of human cancer, predominantly through somatic methy-
lation of the promoter region1,2,13–25. We found 287 somatic
mutations in the OPCML gene from sequencing data within the
COSMIC and TCGA databases. Though these mutations remain
rare, the same amino acid was found mutated in patients with
different cancer types, highlighting the relevance of those resi-
dues. For this reason, we solved the crystal structure of OPCML,
the ﬁrst reported structure from the IgLON family, and mapped
the clinical mutations to its 3D structure in order to possibly help
explain the multiple phenotypes of this tumor suppressor protein.
We previously reported that OPCML interacts with a subset of
RTKs and induces their degradation and/or dephosphorylation
when re-expressed in ovarian cancer cells5,11. This down-
modulation of the RTK network inhibits signalling and pheno-
typic assays deﬁning hallmarks of cancer both in vitro and
in vivo2. However, it was unknown which regions of OPCML
were implicated in the various phenotypes or whether the clinical
mutations identiﬁed here caused loss of OPCML function.
OPCML is composed of three canonical Ig-like domains with a
C-terminal GPI anchor localized in the plasma membrane outer
leaﬂet. Here we demonstrate that OPCML forms a homodimer in
the asymmetric unit, mediated by extensive interactions among
residues in the N-terminal domain D1. We conﬁrmed the
homodimeric arrangement in solution using SAXS, SEC-MALLS,
and gel ﬁltration. Based on the high degree of amino acid con-
servation at this interface in the other IgLON members, we
predict that the same quaternary structure will be found
throughout the IgLON family. With a large proportion of
mutations being present in dimerization domain D1, we hypo-
thesized an important role for D1 in mediating OPCML’s tumor
suppressor functions. To test this hypothesis, we characterized a
protein with the R65L clinical mutation and found this to be
predominantly monomeric in solution, as evidenced by SEC-
MALLS and gel ﬁltration, and also in cells as demonstrated by
non-heated SDS-PAGE. Indeed, this mutant, unlike WT and
despite it being correctly expressed in cells, was unable to block
migration, invasion and anchorage-independent growth, or
in vivo tumorigenicity because it could not interact with RTKs
like AXL and FGFR1 and was thus incapable of inhibiting their
signalling. We noted that OPCML’s afﬁnity for RTKs is strongly
increased upon their RTK dimerization/activation following
ligand binding. Thus it is likely that dimerization of OPCML is
necessary for RTK dimer interactions, thus explaining the
observation of the functional defect in monomeric R65L.
We evaluated N70H clinical mutation to test the effect of
mutating a site that is both glycosylated and buried deep within
the D1-D1 interface, we found the resultant recombinant protein
(secreted using insect cells) to be expressed at low levels and to be
unstable. Although N70H could still bind to RTKs even without
stimulation, which was probably due to its aggregated nature, it
demonstrated a loss of function phenotype in most of the in vitro
assays and an intermediate phenotype in vivo.
Fig. 4 R65L, N70H, and P95R mutants interact differently with AXL and FGFR1. SKOV3 expressing an empty vector (CTRL), wild-type (OPCML) or mutant
(R65L, N70H and P95R) OPCML were simulated for 30min or 3 h with GAS6 (a) or FGF1 (b), and the interaction between OPCML and AXL (a) or OPCML
and FGFR1 (b) was analyzed and quantiﬁed by Proximity Ligation Assay (DuoLink). The values from three independent experiments with ﬁve images each
are shown all together. The bars indicate the mean ± s.e.m. Student t-test: *p < 0.05, ***p < 0.001. c, d Mammalian 2-hybrid assay. Cells were transfected
with the indicated single constructs and the relative empty plasmids (not indicated), or with both plasmids expressing OPCML or P95R plus AXL (c) or plus
FGFR1 (d). The bars indicate the mean ± s.e.m. calculated from the values of all the repeats from three independent experiments. Student t-test compared
to wild-type OPCML plus AXL (c) or OPCML plus FGFR1 (d): ***p < 0.001, ****p < 0.0001. e Gap closure assay. SKOV3 cells expressing the indicated wild-
type and mutant OPCML were serum starved and then left without stimulation (−) or stimulated with GAS6 or FGF1 as indicated. Migration was imaged
after 15 h, and the migration front is highlighted by the dotted lines. Scale bar= 200 μm. f, g SKOV3 cells expressing the indicated wild-type and mutant
OPCML were serum-starved and then stimulated with GAS6 (f) or FGF1 (g) for 30min or 3 h. Cell lysates were analyzed by western blotting for the
expression of total and phosphorylated AKT and ERK. Calnexin was used as loading control. h, i SKOV3 cells expressing the indicated wild-type and mutant
OPCML were treated with the AXL inhibitor R428 for 2 days to assess the IC50 (h) or for 1 day to measure apoptosis (i). Student t-test compares CTRL
and mutants to wild-type OPCML: ***p < 0.001, ****p < 0.0001. Both graphs show the mean ± s.e.m. of three independent experiments
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The crystal structure of OPCML presented here came from
insect cell-expressed material but much of the functional data
employed OPCML from a mammalian source. It is possible that
interactions between glycan at asparagine 70 and protein at the
D1-D1 dimer interface could be different depending on the origin
of the material. Insect cell and human N-linked glycans typically
differ at terminal sialylation sites (present in human not insect)
and occasionally by addition of α1,3-linked fucose at the initial
GlcNac26. We did not observe ordered density extending the
terminal glycans for any of the glycans modeled, nor did we
observe α1,3-linked fucose at the initial GlcNac. Of note, when
the recombinant proteins produced in insect cells were tested in
phenotypic assays (spheroid invasion, Fig. 3f), they showed a loss
of function similar to the mutant proteins produced directly by
the cells. These data indicate functional equivalence between
insect- and mammalian-produced OPCML proteins.
Proline 95 was previously found to be mutated to arginine
causing loss of tumor suppressor phenotype2 and from our
sequence analysis we found it to be mutated eight times to three
different amino acids (the third most commonly mutated residue
after R71 and E201) in patients. The P95R mutation is distal
from the dimerization interface, and the resultant protein was
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Fig. 5Mutations at P95 show similar loss of tumor suppressor function and AXL interaction. SKOV3 cells were transduced with an empty vector (CTRL), wild-
type (OPCML) or mutant (P95R, P95L, P95S) OPCML and analyzed for protein expression/localization by confocal microscopy (a) and protein expression by
western blot (b) with an anti-OPCML antibody. Scale bar= 5 μm. Cells were starved and then stimulated with GAS6 for 30min, 3 h or 12 h as indicated, and the
interaction between OPCML and AXL measured by PLA (c), the signaling to pAKT detected by western blotting (d), the migration tested by gap closure assay
(e) and the invasion studied by 3D spheroid invasion assay in Matrigel (f). GAPDH was used as loading control in b, d. The images were taken with a confocal
microscope in a or an inverted microscope in e and f. Scale bar= 200 μm (e) and 250 μm (f). All the graphs show the mean ± s.e.m. of three independent
experiments. Student t-test compares CTRL and mutants to wild-type OPCML at 24 h of invasion: *p < 0.05, ****p < 0.0001
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10966-8 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3134 | https://doi.org/10.1038/s41467-019-10966-8 | www.nature.com/naturecommunications 9
homodimeric in solution, as shown by SEC-MALLS and gel ﬁl-
tration. In addition, this protein reached the plasma membrane
in cells, and the secreted recombinant protein had a melting
temperature similar to WT, indicating that the loss of tumor
suppressor phenotype was not due to the stability of the
molecule.
Despite the different chemical nature of the substitutions (to
Ser, Arg, or Leu), the disruptive effect of all three mutations was
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Fig. 6 Point mutations in D2 and D3 lead to loss of function. SKOV3 cells were transduced with an empty vector (CTRL), wild-type (OPCML) or mutant
(R71C, E201Q, S203R, R214Q, K230R, K239N, M278I) OPCML and analyzed for protein expression by western blot (a) and protein expression/localization
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(c) and invasion (d) in transwell assays and for anchorage-independent growth in agarose (e). Scale bar= 50 μm (c, d) and 200 μm (e). All the graphs
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similar in our assays and intriguingly, we found that Pro95
mediates the interaction with AXL but not with FGFR1. The fact
that mutations at P95 had selectively lost the interaction with
AXL, the downstream signalling response to GAS6 and the
cognate functional in vitro phenotypes, demonstrates the
structural and functional basis of this clinical mutation. Fur-
thermore, the fact that in vivo suppression of tumorigenicity
was lost with P95R indicated the biological importance of the
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adhesion was tested after 1 h. Values have been normalized to CTRL. Scale bar= 50 μm. All the graphs show the mean ± s.e.m. of three independent
experiments for domains 1 and 2 independent experiments for domains 2 and 3. Student t-test compares CTRL and mutants to wild-type OPCML:
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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AXL pathway in ovarian cancer despite an intact FGFR1/
FGF1 axis.
Additionally, the results described here link IgLON proteins to
extracellular matrix adhesion, demonstrating that OPCML pro-
motes adhesion to collagen but inhibits adhesion to other sub-
strates such as ﬁbronectin and laminin. The mechanism of this
selectivity remains to be established, as OPCML could interact
directly with these substrates and/or interfere with the activity of
other adaptor molecules that bind directly to them. It is inter-
esting to note that residues in each of the three domains are
required to inhibit binding to ﬁbronectin and laminin, while
adhesion to collagen I and IV is D1-speciﬁc, clearly pointing to
the existence of diverse mechanisms for promotion or inhibition
of adhesion to extracellular matrix components.
The only phenotype that did not demonstrate a dependency on
D1 residues was proliferation in vitro, with D1 mutations con-
tinuing to inhibit proliferation, whereas mutations in D2 and D3
lost the ability to suppress proliferation. This suggests that D2
and D3 could mediate the interaction with the binding partners
responsible for inhibition of proliferation.
It is also curious to note that out of the 12 mutants tested, the
only mutation that did not completely impair OPCML’s ability to
inhibit anchorage-independent growth was S203R. Although this
mutation is very close to the E201Q substitution, S203R and E201Q
give opposite phenotypes in this particular assay. It would be
interesting to identify the differential binding partners of these two
mutants to dissect this speciﬁc suppressive function of OPCML.
Concerning tumorigenicity, we had previously shown2 and we
conﬁrm here that OPCML is a potent tumor suppressor that
abrogates tumor growth in in vivo mouse models. Here we
demonstrate that dimerization is key to this function (via the
R65L mutant), and also that the interaction with speciﬁc binding
partners (P95R) is required to inhibit tumorigenesis. The CAM
assay gave similar results and it also demonstrated that mutations
in D2 and D3 affect the inhibition of tumorigenicity, pointing to
the importance of the integrity of the three domains for OPCML’s
full tumor suppressor activity in vivo at least in ovarian cancer.
The quaternary structure of the OPCML homodimer presented
here looks highly similar topologically to that of nectins27. Nectins
are composed of three consecutive Ig-like domains, are also plasma-
membrane-associated and can mediate cell-cell communication via
pairwise cis- and trans- interaction homo- or heterotypically with
other nectin family members. The IgLON family of proteins have
been suggested to pair in a similar fashion8,9 and for these reasons a
possible common mechanism could be suggested.
In summary, in this work we present the crystal structure of
OPCML, identify new phenotypes of this potent tumor sup-
pressor and map diverse functions to distinct protein structural
domains through an understanding of structure/function rela-
tionships associated with clinically occurring cancer missense
point mutations that impair OPCML’s function. Future work will
help to further dissect the mechanisms behind these phenotypes,
with the aim of developing OPCML as a potential therapeutic28 in
cancer patients.
Methods
Protein expression and puriﬁcation. WT human OPCML (UniProt entry
Q14982), R65L, N70H, and P95R were expressed as Fc-fusion proteins in insect
cells after baculovirus infection using Hi5 cells grown in suspension in SFX-insect
serum-free medium. Speciﬁcally, OPCML residues 36–316, corresponding to D1-
D3 were cloned in to the pFastBac1 vector (Invitrogen, USA) downstream of an
N-terminal ceruloplasmin secretion signal (MKILILGIFLFLCSTPLQ) and
upstream of a C-terminal portion composed of ALVPRGS and human IgG1
(Uniprot entry P01857, residues 118–330). The insect cell supernatant was har-
vested 4 days post infection and applied to protein A afﬁnity resin (Repligen). The
resin was washed extensively with PBS pH 7.4 and the OPCML-IgG1 fusion eluted
in 50 mM glycine pH 3.0. After neutralization and buffer exchange into 20 mM
Tris-HCl pH 7.5, 100 mM NaCl and 1 mM CaCl2, the IgG1 tag was removed by
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Fig. 8 Point mutations impair OPCML tumor suppressor function in in vivo models. a SKOV3 cells expressing empty vector (CTRL), wild-type (OPCML) or
mutant (R65L, N70H and P95R) OPCML were injected intraperitoneally in ﬁve female athymic mice each. Tumors and ascites were collected and
measured in grams and milliliters, respectively, as indicated. The mean is indicated by a line in the dot plots. Student t-test compares CTRL and mutants to
wild-type OPCML: *p < 0.05, **p < 0.01. Scale bar= 1 cm. b SKOV3 cells expressing GFP and the indicated constructs were grown embedded in Matrigel on
top of chick chorio–allantoic membranes. Tumors were excised, imaged and the GFP-positive area measured. Scale bar= 500 μm. The graph shows the
mean ± s.e.m. of three eggs. Student t-test compares CTRL and mutants to wild-type OPCML: ***p < 0.001, ****p < 0.0001
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thrombin digestion. Cleaved OPCML was then puriﬁed to homogeneity by nega-
tive puriﬁcation on protein A resin, HiTrap Q HP anion exchange chromatography
(GE Healthcare) and ﬁnally size-exclusion chromatography.
Crystal structure determination. For crystallization, WT OPCML was con-
centrated to 10mgml−1 in 20mM Tris-HCl pH 7.5, 100mMNaCl, and 0.01% NaN3.
Rectangular pyramid-shaped crystals measuring 300 × 300 × 400 µm were obtained at
room temperature by mixing 1 µL of OPCML with 1 µL of precipitant solution. The
best precipitant was found by an iterative process of mixing initial crystal screen hits
back in to the screens29 and was a 50/50 mix (v/v) of 1.6M MgSO4, 100mMMES pH
6.5 and 20% PEG 8000, 100mM HEPES pH 7.5 using the sitting drop vapor diffusion
technique. Platinum derivatives were created by soaking OPCML crystals overnight in
mother liquor supplemented with 10mM K2PtCl4. Crystals were ﬂash-frozen by
mixing 50% mother liquor (v/v) with 50% saturated Li2SO4. Around 5% of all crystals
diffracted maximally to between 3–2.65 Å resolution.
Structure determination/phasing. X-ray diffraction data from native protein
crystals (λ= 0.97931 Å) and Pt-modiﬁed crystals (λ= 1.06929 Å) were collected at
100 °K on the LRL-CAT beamline at the Advanced Photon Source, Chicago, U.S.A.
SBGrid collaborative software library was used throughout the structure determi-
nation process. Diffraction images were processed using IMOSFLM30 and scaled
using SCALA31. Despite extensive searches using a variety of different Ig-domain
containing search models, no molecular replacement solution could be found using
native OPCML diffraction data. These data exhibited strong Patterson peaks
consistent with translational non-crystallographic symmetry that may have
impeded conventional molecular replacement. We evaluated several potential
heavy-atom derivatives, and obtained useful diffraction data in a different space
group from a platinum-soaked crystal. A combined molecular replacement/single-
wavelength anomalous dispersion approach (MR-SAD) as implemented in Phenix
Autosol32 provided a strong solution using the isolated Ig domain 49–124 from
PDB: 1Z9M. This gave 9 platinum sites per asymmetric unit, a ﬁgure of merit of
0.31 and average anamolous difference of 0.0966. Hundred and thirty-ﬁve residues
including 58 side chains were autobuilt, comprising much of D1 and parts of D2
and D3. Phase improvement by density modiﬁcation provided electron density
sufﬁcient to build 104 additional residues from D2 and D3 using COOT33 with
repetitive rounds of reﬁnement using Phenix Reﬁne34.
The partial model derived from MR-SAD phasing of the I4122 Pt derivative
dataset was used as a molecular replacement model to provide initial phasing for
the somewhat higher resolution P41212 native dataset (Table 1). A strong solution
(LLG= 4360 and TFZ= 53.5) was found with two molecules in the asymmetric
unit and conﬁrmed by examination of composite omit maps (Supplemental
Fig. 12). The two molecules were related by a two-fold rotation axis nearly parallel
to the crystallographic (c*) axis, resulting in nearly perfect translational non-
crystallographic symmetry and (x+ 1/2, y+ 1/2, z+ 1/2) pseudocentering.
Examination of the diffraction pattern revealed weaker intensity for the h+ k+ l=
2n spots as compared to the h+ k+ l (not equal to) 2n, with the h+ k+ l= 2n
spots corresponding to those observed for the Pt derivative in the I4122 space
group. An essentially complete model for the OPCML dimer was built by repeated
rounds of model building and reﬁnement as described above. The ﬁnal PHENIX
reﬁnement strategy employed XYZ coordinate, Group-B-factor, TLS and
occupancy reﬁnement with secondary structure restraints. Noncrystallographic
symmetry restraints (NCS) were applied throughout. This gave a ﬁnal model with
Rwork and Rfree of 28.7/30.4, respectively. Final omit electron density is shown in
Supplementary Figure 12.
The overall geometry in the ﬁnal structure is good, with 96% of residues in
favored regions of the Ramachandran plot and no outliers. Clear electron density
was visible for residues corresponding to D1-D3 (residues 42–316) apart from a
loop between the C and Cʹ strands in D2 (residues 175–179 in molecule A and
174–178 in B). Structure ﬁgures were generated using the program PyMOL35.
An analysis of OPCML surfaces, the dimerization interface and crystal contacts
was made possible due to calculations performed by PISA36.
SEC-MALLS. An estimation of the molecular weight of WT, R65L, N70H and
P95R OPCML in solution was given by SEC-MALLS. This was performed on a
chromatography system using a refractive index detector (Optilab T-rEX, Wyatt
Technology) connected to a multi-angle laser light scattering detector (DAWN
HELEOS II, Wyatt Technology). Protein samples (at 1 µg µL−1) were injected and
ran at 1 mLmin−1 in PBS (pH 7.4) buffer at room temperature.
Size-exclusion chromatography and Kd determination. To determine the
binding afﬁnity of OPCML dimerization, various concentrations of WT and R65L
OPCML were subjected to size-exclusion chromatography. Brieﬂy, dilutions of
puriﬁed soluble WT and R65L OPCML were prepared and allowed to equilibrate
for 24 h. Fifty microliters of each dilution were run over a Superdex 200 10/30 GL
column at 0.5 mLmin−1. The resulting chromatograms were normalized to
account for small baseline shifts and slight differences in injection volume. Peak
elution volumes at each dilution were plotted against concentration and ﬁt to the
equation EVobs= EVmonomer+ (1-fractMonomer)(EVdimer− EVmonomer), where
EVobs, is the elution volume observed at particular total protein concentration Ptot,
EVmonomer, and EVdimer are ﬁt values for monomer and dimer elution volumes,
respectively, and fractMonomer is fraction of the total protein concentration
represented by the monomer, determined using the formula fractMonomer=
(−Kd+ sqrt(Kd2+ 8*Ptot*Kd))/4Ptot, where Kd is the ﬁt value for the dimerization
constant37. For estimation of a lower bound on the R65L OPML Kd, EVdim was
constrained to the same value as for WT OPCML. GraphPad Prism 7 software
(USA) was used for curve ﬁtting.
Thermal stability assay. Five microgram of puriﬁed baculovirus-derived recom-
binant WT, R65L, N70H and P95R OPCML were incubated in the presence of 10x
SYPRO Orange (Sigma-Aldrich, Cat. No. S5692) for 1 min at 25 °C, in PBS buffer
(pH 7.4). The ﬂuorescence measurements were recorded in a real-time PCR
machine (Bio-Rad CFX96) from 25 °C in 0.5 °C increments until 95 °C.
Small angle X-ray scattering. SAXS was measured for a sample of WT OPCML.
The sample was dialyzed into 50 mM HEPES pH 7.5, 200 mM sodium chloride, 2%
glycerol, 0.02% sodium azide by equilibration in Hampton Research dialysis but-
tons using a 7 kDa MWCOmembrane. Sample was ﬁltered through 0.22 μm Spin-x
column to remove potential aggregates and two two-fold dilutions were prepared
using dialysate. X-ray scattering was measured using ﬁve one-second exposures
incident on static sample.
Scattering curves were merged and buffer was subtracted by manual
minimization of the water scattering peak at q= 2 Å−1. Scattering curves for the
three concentrations were further merged and the curves were trimmed to the
range 0.0080 < q < 0.190 using SCÅTTER v1.0 software38.
SAXS data was further analyzed using the Fast SAXS Proﬁle Computation with
Debye Formula (FOXS) web server39. Experimental data for OPCML was ﬁt to
calculated SAXS curves originating from the OPCML crystal structure dimer or
monomer model consisting of chain A.
Cell culture. All ovarian cancer cell lines were maintained in RPMI-1640 media
(Sigma-Aldrich) supplemented with 10% Foetal calf serum (FCS, First link),
0.2 mM L-Glutamine (Gibco), penicillin 50 Uml−1, and streptomycin 50 μg ml−1
(Gibco). HEK293T (Human Embryonic Kidney) cells were maintained in Dul-
becco’s Modiﬁed Eagle Medium (DMEM) supplemented as above. HCT116 were
grown in McCoy’s medium supplemented as above. All cell lines were cultured at
37 °C in a 5% CO2 humidiﬁed incubator. Transduced cells were maintained in full
medium supplemented with Puromycin dihydrochloride (Gibco) (10 μg ml−1 for
SKOV3, 5 μg ml−1 for PEA1, and 1 μg ml−1 for PEO1 and HCT116).
SKOV3, HEK293T and HCT116 cells were purchased from ATCC. PEA1 and
PEO1 cells were acquired from Cancer Research UK. All cells were tested regularly
to exclude mycoplasma infection.
Site-directed mutagenesis. Primers were designed using the Quick-change Agi-
lent primer design program available online at www.agilent.com/genomic/qcpd.
The primers were designed to have a complementary sequence ranging from 12–20
bases on either side of the desired mutation site. R65L Forward: 5′- GATGACC
GGGTAACCCTGGTGGCCTGGCTAAAC-3′; N70H Forward: 5′- CGGGTGGC
CTGGCTACACCGCAGCACCATCCTC-3′; R71C Forward: 5′- GTGGCCTGGC
TAAACTGCAGCACCATCCTCTAC-3′; P95R Forward: 5′- ATCATCCTGGTC
AATACACGAACCCAGTACAGCATCATG-3′; P95L Forward: 5′-ATCATCCT
GGTCAATACACTAACCCAGTACAGCATCATG-3′; P95S Forward: 5′-ATCA
TCCTGGTCAATACATCAACCCAGTACAGCATC-3′; E201Q Forward: 5′-CA
GTCCGGGGAGTACCAATGCAGCGCGTTGAAC-3′; S203R Forward: 5′-GG
GGAGTACGAATGCCGCGCGTTGAACGATGTC-3′; R214Q Forward: 5′-GCT
GCGCCCGATGTGCAGAAAGTAAAAATCACT-3′; K230R Forward: 5′-CCCTA
TATCTCAAAAGCCAGGAACACTGGTGTTTCAGTC-3′; K239N Forward: 5′-G
TTTCAGTCGGTCAGAACGGCATCCTGAGCTGT-3′; M278I Forward: 5′-G
AAAACAAAGGCCGCATCTCCACTCTGACTTTC.
Mutagenesis reactions were performed following a Quick-Change® Site-
Directed Mutagenesis protocol (Agilent) using Pfu DNA Polymerase (Thermo
Scientiﬁc). The plasmid DNA template, used to generate the desired mutants, was
pENTR4 containing the OPCML WT cDNA. The mutagenesis reaction was
prepared to make a ﬁnal volume of 20 μl that contained the following components:
up to 20 μl of autoclaved distilled water; 2 μl of 10x buffer+MgSO4; 0.5 μl of
25 mM dNTPs; 1 μl of each mutagenic primer (100 ng μl−1); 20 ng μl−1 plasmid
DNA template; 1 μl of Pfu DNA Polymerase; (Thermo Scientiﬁc, UK) and 3%
DMSO. The reaction mixture was run in the MJ Research PTC-200 PCR Thermal
Cycler—GMI. After the reaction was completed, it was incubated with 1 μl of DpnI
restriction enzyme (New England Biolabs®, UK) at 37 °C for one hour. The
digested mutagenesis product was then transformed into competent bacterial cells.
The mutations were conﬁrmed by DNA sequencing.
Single domain cloning. D1 (Pro39-Ser126), D2 (Arg127-Thr219), and D3
(Val229-Tyr310) constructs were purchased from Life Technologies designed as
entry clones. All constructs have a signal sequence for secretion in the N-terminus
and an HA tag at the C-terminus before the GPI-anchor attachment site.
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The Gateway® cloning system. Sequenced WT and mutant pENTR4-OPCML
plasmids were used to shuttle the sequence of interest to the Destination vector,
pLenti CMV Puro DEST. Reactions were carried out mixing 50 ng of entry vector
and 150 ng of destination vector with 1X LR Clonase reaction buffer in a total
volume of 10 µl. Reactions were incubated at 25 °C for 1 h, after which 4 µg of
proteinase K (GatewayTM LR Clonase II Enzyme Mix, Invitrogen) was added and
samples were incubated for further 10 min at 37 °C. Then, 1 µl of reaction was used
for bacterial transformation using HB101 competent cells. The plasmids were
ampliﬁed and puriﬁed.
Transfection. Human Embryonic Kidney (HEK293T) cells were used to produce
lentivirus. The cells were seeded into 60mm tissue culture dishes at 3 × 106, 24 h
before Lipofectamine 2000™ transfection following the reagent protocol (Invitrogen).
Four microgram of pLenti CMV Puro DEST were mixed with 3.5 µg of packaging
plasmid (p8.9) and 0.5 µg of envelope (pMDG) in 500 µl of Opti-MEM medium, and
incubated for 5min at room temperature. At the same time 20 μl of Lipofecta-
mine™2000 were diluted in 500 μl of Opti-MEMmedium and also incubated for 5min.
After the incubation, the two solutions were mixed and incubated at room temperature
for a further 20min. The transfection complex was added to the cells drop-wise,
incubated for six hours after which the medium was changed to full growth medium
with antibiotics (Penicillin/Streptomycin). After 48 h, the virus was collected and
underwent centrifugation at 1000×g for 4min, after which it was ﬁltered using 0.20 µm
ﬁlters. Aliquots were made into 1.5 Eppendorf tubes and frozen at −80 °C.
Transduction. Ovarian cancer cell lines (SKOV3, PEA1, and PEO1) were seeded
into 24-well plates to suitable density, transduced with different amounts of virus
(50–450 μl) and incubated for 24 h before changing the medium and adding the
selective antibiotic (Puromycin). Cells were then expanded and protein over-
expression tested by western blot.
Whole cell lysate preparation. Cultured mammalian cells in six-well plate were
lysed in 100 µl of RIPA buffer (25 mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS) supplemented with phosphatase (Merck
Millipore) and protease inhibitors (Roche and Sigma-Aldrich). Cells were lysed on
ice for 15 min, collected into Eppendorf tubes and subjected to centrifugation at
16000×g for 20 min at 4 °C. After centrifugation, supernatants were transferred to
new Eppendorf tubes and used for protein concentration determination using the
BCA protein assay kit (Pierce), following manufacturer’s instructions.
Western blot. Protein samples (5–10 µg) were separated on 8–10% gels by SDS-
PAGE and transferred onto a nitrocellulose membrane (Merck, Millipore). The
membrane was then blocked and incubated with the desired primary antibodies
diluted 1:1000: anti OPCML (goat pAb, #AF2777, R&D Systems), phospho-AKT
(Thr308 D25E6 XP® rabbit mAb, #13038, Cell Signaling), AKT (pan 11E7 rabbit mAb,
#4685 Cell Signaling), phospho-ERK1 (pT202/pY204)+ phospho-ERK2 (pT185/
pY187) (mouse mAb, ab50011, Abcam), ERK1/2 (rabbit pAb, ab17942, Abcam) and
anti-GAPDH (Cell Signalling), over-night at 4 °C. The membrane was washed, then
incubated with the appropriate secondary antibodies (DAKO) diluted 1:5000. After
ﬁnal washings, proteins were detected using Immobilon Western Chemiluminescent
HRP Substrate system (Millipore) and GE Healthcare Amersham™ Hyperﬁlm™ ECL
ﬁlm with a Kodak SRX2000 (Rochester, NY, USA) developer machine.
Immunoﬂuorescence confocal microscopy. Coverslips with adherent monolayer
cells were rinsed twice in PBS, ﬁxed with ice-cold methanol for 5 min at −20 °C
and then washed again. The coverslips were blocked with 3% Bovine serum
albumin (BSA) for 30 min at room temperature, and then incubated with the anti-
OPCML (mouse mAb, #MAB27771, R&D Systems) antibody diluted 1:100 at room
temperature for 1 h in a wet chamber, washed and incubated with a suitable
secondary antibody diluted 1:400 at room temperature for 30 min. Coverslips were
mounted with a drop of Prolong gold 4′, 6-diamidino-2-phenylindole (DAPI)
(Invitrogen) and left to dry in the dark at room temperature overnight before being
examined under an SP5 confocal microscope (Leica).
Cell migration and invasion assays. Cell migration and invasion assays were
performed using 8 μm pore PET Membrane chambers for 24-well plates (Corning,
UK). Cells were grown in full medium and then re-suspended in serum-free media
when added to chambers with or without Matrigel. 2.5 × 104 cells/chamber were
seeded in duplicate. Cells were allowed to migrate/invade for 24 h, after which the
cells that had not migrated/invaded were removed with a cotton swab from inside
the chamber and the inserts washed in PBS. Cells were ﬁxed with ice-cold methanol
and stained with 0.1% crystal violet in 25% methanol. At least six images were
taken for each insert at ×10 magniﬁcation using a Nikon Eclipse TE2000-U
microscope and QCapture Pro software. Analysis and quantitation were performed
using ImageJ. The data were obtained from three independent experiments and
each experiment was performed in duplicate.
Soft agar colony formation assay. Anchorage-independent growth was assessed
by plating 0.8 × 104 cells in 2 ml of 0.6% Noble agar agarose (Difco, USA) over a
base of 1% Noble agar in six-well plates. Cells were allowed to grow for 4–6 weeks,
during which the media was replaced every week, and colonies formed were
visualized by adding 0.015% neutral red in PBS to the media. Images were captured
using a custom TE2000-V inverted microscopes with a digital camera (Nikon, UK).
The data were obtained from three independent experiments and each experiment
was performed in triplicate.
rOPCML in tumor spheroids invasion assay in Matrigel®. Five thousand SKOV3
cells were seeded in triplicate in ultra-low attachment U bottom 96-well plates and
cultured in RPMI supplemented with 10% FCS at 37 °C, 5% CO2. After 5 days the
spheroids were formed and the medium was reduced of growth factors through a
series of passages in RPMI deprived of FCS supplement. The spheroids were serum
starved overnight, treated with 40 µg ml−1 of WT rOPCML or rOPCMLs carrying
the R65L, N70H and P95R mutations produced from baculovirus infected insect
cells, and then stimulated with 10% FCS. PBS used for the buffer exchange in the
ﬁnal steps of rOPCML puriﬁcation was used in control to identify any off-target
effect due to rOPCML preparation. After 3 h, Matrigel® reduced of growth factor
and without phenol red was added to the culture at a 1:1 ratio with the medium.
Spheroids were allowed to invade the matrix and images were taken with the Nikon
Eclipse TE2000 digital light microscope at 0 h and 72 h at ×4 magniﬁcation. Images
were analysed with Image J software, and the measurement were expressed as a
ratio of invading area over the spheroid area. The data were obtained from two
independent experiments and each experiment was performed in triplicate.
Kinetic stimulation studies with GAS6 and FGF1. The cell lines were seeded to
attain 70% conﬂuence, serum starved overnight and activated with 400 ng mL−1
GAS6 (#885-GS, R&D Systems) or 10 ng mL−1 FGF1 for 0, 30 min and 3 h and
lysates were collected for western blot analysis.
DUOLink proximity ligation ampliﬁcation (PLA) assay. For PLA assay (DUO-
Link, OLink Biosciences, Sigma-Aldrich #DUO92102, #DUO92104), the various
cell lines were seeded on 13 mm glass coverslips. After the required treatments, the
initial part of the immunoﬂuorescence protocol was followed to label the ﬁxed cells
with primary antibodies diluted 1:100 from two different species (e.g., mouse anti-
OPCML, and rabbit anti-AXL). The rest of the protocol was followed as per
manufacturer’s instructions.
Gap closure assays. The cell lines were seeded at 100% conﬂuence into culture
inserts (ibidi #80209) in a 24-well plate and serum-starved overnight. The insert was
removed to generate a 500 μm gap, and cells were stimulated with 400 ngmL−1
GAS6 or 10 ngmL−1 FGF1. Control cells were not stimulated. The cells were
visualized under the microscope 18 h later.
Mammalian 2-hybrid. OPCML was cloned in the pM vector downstream of the
SV40 promoter and GAL4 DNA binding domain, while the extracellular domains
of AXL and FGFR1 were cloned in the pVP16 vector downstream of the SV40
promoter and VP16 activation domain. COS-1 cells were transiently transfected at
80% conﬂuence in 24-well plates for 2–3 h with 50 ng of the pGAL4 Luc reporter,
50 ng of each of the different pM and pVP16 constructs and 50 ng of the β-gal
transfection control plasmid using Effectene® Transfection Reagent (Qiagen) at a
1:10 DNA to Effectene reagent ratio. Cells were then washed with 1X PBS and
incubated in full medium overnight. Cells were collected in 1X Cell Culture Lysis
Reagent (CCLR) from the Promega Luciferase Assay System and incubated at
−80 ˚C for 30 min. Luciferase activity was measured by adding lysates and Luci-
ferase Assay Substrate in Assay buffer (Promega) in equal volumes to white ﬂat-
bottomed 96-well plates (PerkinElmer) followed by reading with a VICTOR™
XLight Luminescence Plate Reader (PerkinElmer) using the emission ﬁlter slot A7.
Transfection efﬁciency was measured using the Galacto-Light Plus™ beta-
Galactosidase Reporter Gene Assay System (Applied Biosystems) according to the
manufacturer’s guidelines. Each experiment was carried out in quadruplicate, and
the luciferase measurements were normalized for the β-galactosidase readings and
are expressed as mean ± standard error of mean (s.e.m).
R428 IC50. Cells were seeded in a 96-well plate at 5000 cells/well and treated the
following day with different concentrations of the AXL inhibitor, R428 (Sell-
eckchem). Cell viability was evaluated 48 h later using the CellTiter MTS cell
proliferation assay (Promega, USA). The experiment was repeated at least three
times with a minimum of three replicates, and IC50 values were calculated through
GraphPad Prism software (USA).
Apoptosis assay. Cells were seeded and treated as above. One plate was used to
assess the levels of apoptosis using the Caspase-Glo® 3/7 Assay (Promega, UK),
which measures cleaved Caspase-3 and Caspase-7 activities, whereas the second
plate was used to determine viable cells by MTS proliferation assay (Promega,
USA). The assay was performed according to manufacturer’s guidelines. Brieﬂy,
following drug treatment, an equal volume of Caspase-Glo® 3/7 reagent was added
to each well and plates were incubated for 1 h at room temperature. Luminescence
was measured using a LUMIstar OPTIMA microplate reader (BMG Labtech, UK).
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Proliferation assay. To study cell proliferation, we used MTS-1 proliferation assay
(Promega). Cells were seeded at 2000 cells/well in 100 μl in a 96-well plate, and
baseline readings were taken on the same day of the seeding as soon as the cells
settled. For baseline and each time-point (6, 24, 48, 72, 96 h), 10 μl of MTS-1 solution
was added to each well, incubated for 1 h and absorbance was measured at 490 nm.
Cell adhesion assay. Cell adhesion onto Fibronectin, collagen I, collagen IV,
Laminin I and Fibrinogen was evaluated using the CytoSelect cell adhesion assay
(Cell Biolabs, USA), according to the manufacturer’s protocol. Cells were sus-
pended in serum-free media at a concentration of 1 × 106 cell ml−1. A total of
150 μl (1.5 × 105 cells) were seeded into each well of a plate pre-coated with dif-
ferent ECM proteins. The plate was incubated at 37 °C for 90 min, after which time
the wells were gently washed ﬁve times with PBS, followed by staining with cell
stain solution (0.09% crystal violet) for 10 min at room temperature. Wells were
then washed ﬁve times with deionized water, and the plate was left to dry before
dissolving cells in 200 μl of cell extraction solution (10% acetic acid) and incubating
on an orbital shaker for 10 min. One hundred and ﬁfty microliter of each extract
sample was ﬁnally transferred into a 96-well plate, and the optical density (OD)
was measured at 560 nm in computer-interfaced 96-well tunable microtiter plate
reader (OPTImax Molecular Devices).
Animal welfare. All the procedures involving mice or chicken embryos were
performed in agreement with Community and National legislation (Directive 2010/
63/EU; Animals Scientiﬁc Procedures Act 1986) and also in agreement with the
Basel Declaration. The experimental protocol received prior approval by the
competent National Authority (project licence reference: PPL 70/7997) and by the
Imperial College’s Animal Welfare and Ethical Review Body.
Mouse model. Eight-week old athymic female mice were injected intraperitoneally
with 5 × 106 cells in 200 ml of PBS. Mice were sacriﬁced after 10 weeks by Schedule
1 methods. Ascites was aspirated with a needle. Tumors were removed and
weighted.
Chick chorioallantoic membrane model. Fertilized chicken eggs were purchased
from Henry Stewart & Co. Ltd (Fakenham, UK), cleaned and incubated at 37.5 °C
with 50% relative humidity on embryonic day (ED) 0, for implantation on ED9.
Under sterile conditions, a small hole was pierced through the egg’s taglion using a
19 G needle and 3 mL of albumen were removed to decrease the volume inside the
egg and to ensure that the Chick chorioallantoic membrane (CAM) is not damaged
when the egg shell is opened. Semi-permeable sterile tape was placed over the top
of the egg’s shell and sharp angled scissors were used to excise the shell and cut a
2 cm2 window to expose the CAM. This window was sealed with Suprasorb® F
sterile wound-healing ﬁlm (Lohmann & Rauscher, Germany). Between ED7 and
ED10 of incubation, the membranes were ready for the grafting of cancer cells. On
ED9, grafts were prepared by suspending 106 cells in 100 μl of Matrigel (BD
Biosciences) and gently deposited onto the membrane. After inoculation, the
window was then re-covered and sealed, then the eggs were placed back in the
incubator. Tumor growth and viability of the embryo was checked daily. Tumor
dimensions were measured using SteREO Discovery.V8 microscope (Zeiss, Ger-
many) with Zen 2.0 blue edition software (Zeiss).
Data analysis. Images were compiled in Image J. Data were analysed using Graph
Pad Prism 7. Results are presented as mean ± s.e.m. unless otherwise indicated.
Statistical analysis was performed with two-tailed student’s T-test as appropriate. A
p-value < 0.05 was considered signiﬁcant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The atomic coordinates and structure factors for the crystal structure of the OPCML
protein determined in this study have been deposited in the Protein Data Bank with
accession code 5UV6 https://www.rcsb.org/structure/5UV6. All other data generated or
analyzed during this study are included in this published article (and in its accompanying
Supplementary Information). A source data ﬁle is available for this manuscript.
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